Active Ingredient(s): Fedratinib Hydrochloride
FDA Approved: * August 16, 2019
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Inrebic Overview

Fedratinib, sold under the brand name Inrebic, is an anti-cancer medication used to treat myeloproliferative diseases including myelofibrosis.[3] It is used in the form of fedratinib hydrochloride capsules that are taken by mouth. It is a semi-selective inhibitor of Janus kinase 2 (JAK-2).[3][4] It was approved by the FDA on 16 August 2019.[3] Myelofibrosis is a myeloid cancer associated with anemia, splenomegaly, and constitutio...

Read more Inrebic Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Inrebic Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Fedratinib Hydrochloride
  • Capsule: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Inrebic: (1 result)

Sorted by National Drug Code
  • 59572-720 Inrebic 100 mg Oral Capsule by Celgene Corporation

Other drugs which contain Fedratinib Hydrochloride or a similar ingredient: (1 result)